



Atrion Corporation (ATRI)

Updated March 29th, 2024, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$464	5 Year CAGR Estimate:	3.1%	Market Cap:	\$830.6 M
Fair Value Price:	\$444	5 Year Growth Estimate:	2.0%	Ex-Dividend Date:	03/14/2024
% Fair Value:	105%	5 Year Valuation Multiple Estimate:	-0.9%	Dividend Payment Date:	03/29/2024
Dividend Yield:	1.9%	5 Year Price Target:	\$490	Years Of Dividend Growth:	21
Dividend Risk Score:	C	Retirement Suitability Score:	D	Rating:	Hold

Overview & Current Events

Atrion Corporation (ATRI) develops and manufactures products for medical applications. The company's medical products are used in several fields, including cardiovascular, fluid delivery, and ophthalmic applications. The company's fluid delivery products contribute to a significant portion of the company's revenue, accounting for 47% of net revenues for 2021. Cardiovascular products of the company, like Myocardial Protection System, are also popular among customers and formed 34% of the company's sales in 2021. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion Corporation generates the majority of its revenue in the United States.

On February 29th, 2024, Atrion Corporation announced its Q4 2023 results, posting non-GAAP adjusted diluted EPS of \$3.65, compared to \$4.70 for the fourth quarter of 2022, and total revenues of \$43.6 million. The full-year figures showed a more pronounced downturn, with revenues falling 8% to \$169.3 million and net income dropping 45% to \$19.4 million, culminating in a diluted EPS of \$11.02. President and CEO David Battat attributed the annual declines to global supply chain disruptions that impacted the production of key products and an inventory adjustment by OEM customers. Despite the setbacks, Battat underscored Atrion's resilience and future growth strategies, including maintaining workforce levels, renewing multi-year supply agreements, and expanding its product pipeline and factory capabilities. Looking forward, Atrion is optimistic about 2024, projecting a high single-digit revenue increase and an improvement in operating income in the second half of the year, bolstered by a debt-free status and \$14.4 million in cash and investments.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$14.08	\$15.47	\$14.85	\$19.71	\$18.44	\$19.73	\$17.44	\$18.81	\$19.56	\$11.02	\$12.00	\$13.25
DPS	\$0.64	\$0.75	\$0.90	\$1.05	\$1.20	\$1.35	\$1.55	\$7.40	\$8.20	\$8.70	\$8.80	\$11.23
Shares¹	2.0	1.9	1.9	1.9	1.9	1.9	1.8	1.8	1.8	1.8	1.8	1.7

As inflation normalizes and interest rates peak, we expect the company to stabilize margins for the foreseeable future as it had before the expansion. In addition, Atrion Corporation's new company-wide ERP system and a sizable expansion of the Florida facility will enable the expansion of capacity and meet higher demand.

With production of MPS 3 consoles at record levels and new partnerships underway, Atrion anticipates a return to growth in 2024, expecting a high single-digit revenue increase and improved operating income in the latter half of the year, supported by a debt-free position and significant cash reserves. Therefore, we have revised our EPS estimate for 2024 at \$12.00, but we have maintained the low growth forecast at 2.0% through 2029, leading to an EPS estimate of \$13.25 by 2029. The company will also be able to grow its dividends at a healthy but slower pace in the future. We have assumed a dividend growth rate of 5.0% for the next five years.

¹ Shares in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Atrion Corporation (ATRI)

Updated March 29th, 2024, by Yiannis Zourmpanos

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	21.9	23.9	28.9	29.8	35.4	40.8	36.4	35.3	32.1	45.8	38.7	37.0
Avg. Yld.	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	1.1%	1.3%	1.7%	1.9%	2.3%

Atrion Corporation is trading at a forward P/E of 38.7, slightly ahead of its five-year average P/E of 37.6. There is a potential for a slight re-rating if the company posts solid results amidst a challenging environment. Given the current environment of interest rates, consistent long-term growth, and prospective M&A activity that could make ATRI an attractive target, we maintain our target of P/E at 37.0. This is slightly higher than the company's 5-year average P/E, suggesting a target price of \$490.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	5%	5%	6%	5%	7%	7%	9%	39%	42%	79%	73%	85%

Atrion Corporation's solid cash generation ability is reflected in its solid payout ratio over the years. The company's five-year average payout ratio stands at 30.4%, and the company has been able to grow dividends at a CAGR of 48.6% during this time. Finally, Atrion Corporation has consistently increased its dividend payment to shareholders for 21 years. In addition, the company is at low risk of being impacted by a possible recession since its products don't fall into the discretionary category. However, it is to be noted that the company is a relatively small player in the industry, and some of its competitors have greater financial resources and the ability to invest heavily in R&D to help them capture more market share in the future.

Final Thoughts & Recommendation

As a defensive healthcare company, Atrion Corporation and its stock should be able to perform well. However, the disappointing results in 2023 are concerning, yet management has provided a hopeful outlook, suggesting a potential return to growth in 2024. Our hold rating is premised upon the 3.1% annualized total returns for the medium-term, stemming from forecasted earnings-per-share growth of 2.0%, the 1.9% dividend yield, and a small valuation headwind.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Atrion Corporation (ATRI)

Updated March 29th, 2024, by Yiannis Zourmpanos

Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Revenue	132	141	146	143	147	152	155	148	165	184
Gross Profit	63	69	71	68	71	72	71	66	69	76
Gross Margin	47.8%	48.7%	48.7%	47.1%	48.3%	47.1%	45.6%	44.8%	42.0%	41.3%
SG&A Exp.	21	22	22	22	24	25	25	25	28	31
D&A Exp.	9	9	9	9	9	9	11	12	13	14
Operating Profit	38	41	43	39	41	42	41	36	36	40
Op. Margin	28.7%	29.0%	29.2%	27.3%	28.2%	27.4%	26.1%	24.2%	21.8%	21.7%
Net Profit	27	28	29	28	37	34	37	32	33	35
Net Margin	20.1%	19.8%	19.8%	19.2%	25.0%	22.5%	23.7%	21.8%	20.0%	19.0%
Free Cash Flow	27	19	31	27	37	26	22	17	23	(5)
Income Tax	13	14	12	12	6	8	6	6	5	6

Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Total Assets	172	172	164	182	204	231	262	267	267	265
Cash & Equivalents	29	21	28	20	30	59	45	22	32	5
Acc. Receivable	14	17	17	17	17	17	19	16	21	24
Inventories	26	28	30	29	29	34	42	50	51	66
Goodwill & Int.	13	12	12	12	12	11	11	11	11	11
Total Liabilities	23	22	20	19	19	20	24	26	23	25
Accounts Payable	4	5	4	4	4	5	6	7	7	12
Long-Term Debt	-	-	-	-	-	-	-	-	-	-
Total Equity	149	150	144	163	184	211	238	240	244	240
LTD/E Ratio	-	-	-	-	-	-	-	-	-	-

Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Return on Assets	16.2%	16.2%	17.2%	15.9%	19.0%	15.7%	14.9%	12.1%	12.4%	13.2%
Return on Equity	18.7%	18.6%	19.7%	18.0%	21.1%	17.3%	16.4%	13.4%	13.6%	14.5%
ROIC	18.7%	18.6%	19.7%	18.0%	21.1%	17.3%	16.4%	13.4%	13.6%	14.5%
Shares Out.	2.0	2.0	1.9	1.9	1.9	1.9	1.9	1.8	1.8	1.8
Revenue/Share	65.44	71.27	77.93	77.27	78.94	82.05	83.23	80.17	90.76	102.52
FCF/Share	13.35	9.39	16.63	14.41	20.12	13.85	11.82	9.42	12.63	(2.76)

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.